17 October 2019 - Topical atopic dermatitis treatment Elidel now available for children three months and over.

Bausch Health today announced that Health Canada has approved the extension of the indication of Elidel (1% pimecrolimus cream), its prescription treatment for mild to moderate atopic dermatitis, commonly known as eczema, to include patients three months of age and older instead of two years as was previously indicated. 

Additionally, under the Warnings and Precautions section, the long-term use and safety limitations of Elidel have been removed. The changes are based on Health Canada's review of data.

Read Bausch Health press release